Interpace Biosciences

Interpace Biosciences Current Liabilities

The Current Liabilities of Interpace Biosciences (IDXG) as of Oct 17, 2026 is 1.64 M USD. In the previous year, Current Liabilities was 10.32 M USD — a change of -84.08% (lower).

Current Liabilities

1.64 MUSD

YoY

-84.08%

Last updated:

Current Liabilities of Interpace Biosciences is 2025 1.64 M USD. Current Liabilities of Interpace Biosciences was 2024 10.32 M USD. It decreases by -84.08% lower compared to the previous year.

The Interpace Biosciences Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
13.89 M USD
Jan 1, 2019
26.29 M USD
Jan 1, 2020
29.83 M USD
Jan 1, 2021
14.45 M USD
Jan 1, 2022
10.41 M USD
Jan 1, 2023
10.69 M USD
Jan 1, 2024
10.32 M USD
Jan 1, 2025
1.64 M USD
The Interpace Biosciences Current Liabilities history
YEARCurrent LiabilitiesYoY
1.64 MUSD-84.08%
10.32 MUSD-3.45%
10.69 MUSD+2.68%
10.41 MUSD-27.97%
14.45 MUSD-51.57%
29.83 MUSD+13.47%
26.29 MUSD+89.26%
13.89 MUSD-26.03%
18.78 MUSD-52.82%
39.80 MUSD+28.92%
30.87 MUSD-53.81%
66.83 MUSD+25.39%
53.30 MUSD-2.90%
54.89 MUSD-23.95%
72.18 MUSD+3.22%
69.93 MUSD+70.64%
40.98 MUSD-27.80%
56.76 MUSD+20.54%
47.09 MUSD-30.13%
67.39 MUSD-28.53%
94.29 MUSD-4.93%
99.18 MUSD-33.85%
149.94 MUSD+24.30%
120.63 MUSD-57.31%
282.54 MUSD+36.24%
207.38 MUSD+402.14%
41.30 MUSD+54.68%
26.70 MUSD+97.78%
13.50 MUSD+53.41%
8.80 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Interpace Biosciences Stock analysis

What does Interpace Biosciences do? Interpace Biosciences Inc., headquartered in Parsippany, New Jersey, develops and sells diagnostic clinical and pharma services. The company offers five commercialized molecular tests and one in clinical evaluation, including PancraGEN for pancreatic cancer diagnosis, PanDNA for a limited factor snapshot, ThyGeNEXT for thyroid cancer evaluation, ThyraMIR v2 for thyroid cancer diagnosis, and RespriDX to differentiate lung cancer origins. With 94 employees, it operates in the Health Care sector, focusing on molecular diagnostics and bioinformatics solutions for cancer risk assessment. Interpace Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Interpace Biosciences stock

Current Liabilities of Interpace Biosciences is 1.64 M USD in 2025.

Current Liabilities of Interpace Biosciences changed from 10.32 M USD to 1.64 M USD, representing a -84.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Interpace Biosciences since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Interpace Biosciences historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Interpace Biosciences

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Interpace Biosciences